Dr Chichagova will be talking about Retinitis Pigmentosa, one of the most common forms of inherited blindness affecting over 1 million people worldwide.With no effective treatment available for Retinitis…
Read updateUsing statistical modelling, Dr Chichagova was able to improve the differentiation outcome of human induced pluripotent stem cells to retinal organoids, which were subsequently successfully tested with a toxicologically relevant test compound. As…
Read updateHilton Gateshead – 16th-18th April https://www.thebts.org/bts-annual-congress-2018/ The Newcells Biotech team will be attending the British Toxicological Society Annual Congress 2018 that is taking place in Gateshead on 16th-18th April. Newcells Biotech staff…
Read updateNewcells Biotech has joined the StemBANCC project, a pan-EU consortium made up of major pharmaceutical and academe groups. StemBANCC’s goal is to generate 1,500 iPSC lines from 500 people,…
Read updateWorking with academics Prof Mark Birch-Machin and Dr Peter Hanson from the Institute of Cellular Medicine, Newcells is using its expertise in cellular reprogramming and differentiation of iPSCs to…
Read updateThe agreement will enable Newcells to develop, manufacture, distribute products and offer services to customers based on reprogramming cells using the CytioTuneTM-iPS kit. Prof Lyle Armstrong, CSO of Newcells Biotech,…
Read updateThe agreement will enable Newcells to develop, manufacture, distribute products and offer services to customers in the pharmaceutical, biotechnology and academic sectors in Europe. Dr Mike Nicholds CEO of Newcells…
Read update